News | September 20, 2024
Abbott India inks non-exclusive patent license agreement with Takeda for Vonoprazan
This license will enable Abbott to enhance access to this novel therapy to more patients across India
This license will enable Abbott to enhance access to this novel therapy to more patients across India
She brings an overall Techno Commercial experience of 22+ Years in various Organizations
Bumetanide Injection USP (RLD Bumex) had estimated annual sales of USD 20 million in the U.S.
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
The primary objective was to evaluate safety and tolerability of Ropanicant in patients with MDD
Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India
He has been associated with Caplin Steriles Ltd., Mylan Laboratories Ltd., Caplin Point Laboratories Ltd., Strides Arcolab Ltd. and Novartis Vaccines and Diagnostics
Total investment incurred for setting up the new R&D Rs 250 crore
Fluoxetine Tabs 60 mg approval solidifies the company's position in the molecule by complementing the recent approval in April 2024 for Fluoxetine 10 mg and 20 mg tablets and Fluoxetine capsules
India's bio economy has experienced remarkable growth, skyrocketing from US $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030
Subscribe To Our Newsletter & Stay Updated
